Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Flaws In China’s Drug Regulatory Process Revealed In Herbal Injection Recall

This article was originally published in PharmAsia News

Executive Summary

China's Ministry of Health and State FDA have issued an urgent notice to recall two batches of Ciwujia injection produced by Wandashan Pharmaceutical after adverse effects resulting in three deaths were reported. Although the investigation is still ongoing, experts think that the deaths were mainly caused by impurities in the herbal injection. For food and drug supervision, China currently only tests active components. Control is lax on impurities testing; furthermore, the complex nature of traditional Chinese medicine components means some impurities cannot be detected. Industry analysts observe that despite the country's repeated adverse drug incidents, the negative impact on TCM injections will probably be short term as the products still have big market potential due to their low cost. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts